MEK1/2 inhibition suppresses tamoxifen toxicity on CNS glial progenitor cells

Journal of Neuroscience

Volumn 33, Issue 38, 2013, Pages 15069-15074

  Chen, Hsing Yu ^a   Yang, Yin Miranda ^a,b   Han, Ruolan ^a   Noble, Mark ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Stemgent   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1, 4 DIAMINO 1, 4 BIS (2 AMINOPHENYLTHIO) 2, 3 DICYANOBUTADIENE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; SELUMETINIB; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL DEATH; CELL VIABILITY; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS CALLOSUM; DENTATE GYRUS; DRUG SCREENING; FEMALE; GLIA CELL; HUMAN; HUMAN CELL; MOUSE; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL;

ANIMALS; BENZIMIDAZOLES; BREAST NEOPLASMS; CELL COUNT; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IN SITU NICK-END LABELING; MAP KINASE KINASE 1; MICE; MICE, INBRED CBA; NEUROGLIA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STEM CELLS; TAMOXIFEN;

EID: 84884172692     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2729-13.2013     Document Type: Article

References (42)

1. Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL (2001) Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage 21:407- 424. CrossRef Medline
2. Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC (2012) A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 30: 1216-1223. CrossRef Medline
3. Brown MS, Stemmer SM, Simon JH, Stears JC, Jones RB, Cagnoni PJ, Sheeder JL (1998) White matter disease induced by high-dose chemotherapy: longitudinal study withMRimaging and proton spectroscopy. AmJ Neuroradiol 19:217-221. Medline
4. Chen HY, Yang YM, Stevens BM, Noble M (2013) Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. EMBO Mol Med 5:723-736. CrossRef Medline
5. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6:2209-2219. CrossRef Medline
6. Dietrich J (2010) Chemotherapy associated central nervous system damage. Adv Exp Med Biol 678:77-85. CrossRef Medline
7. Dietrich J, Noble M, Mayer-Proschel M (2002) Characterization of A2B5_glial precursor cells from cryopreserved human fetal brain progenitor cells. Glia 40:65-77. CrossRef Medline
8. Dietrich J, Han R, Yang Y, Mayer-Pröschel M, Noble M (2006) CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5:22. CrossRef Medline
9. Dringen R (2000) Metabolism and functions of glutathione in brain. Prog Neurobiol 62:649-671. CrossRef Medline
10. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ (2004) Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage 21:364 -371. CrossRef Medline
11. Encinas JM, Vazquez ME, Switzer RC, Chamberland DW, Nick H, Levine HG, Scarpa PJ, Enikolopov G, Steindler DA (2008) Quiescent adult neural stem cells are exceptionally sensitive to cosmic radiation. Exp Neurol 210:274-279. CrossRef Medline
12. Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, Coker LH, Gaussoin SA, Stefanick ML, Lane DS, Maki PM, Resnick SM (2010) Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health (Larchmt) 19:371-379. CrossRef
13. Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, Fattorossi A, Isola G, Benedetti Panici P, Mancuso S (1999) Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 79:257-263. CrossRef Medline
14. Fyffe-Maricich SL, Karlo JC, Landreth GE, Miller RH (2011) The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation. J Neurosci 31:843-850. CrossRef Medline
15. Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, Decensi A, Lien EA (2012) Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat 134: 693-700. CrossRef Medline
16. Gläscher J, Rudrauf D, Colom R, Paul LK, Tranel D, Damasio H, Adolphs R (2010) Distributed neural system for general intelligence revealed by lesion mapping. Proc Natl Acad Sci U S A 107:4705-4709. CrossRef Medline
17. Guardiola-Diaz HM, Ishii A, Bansal R (2012) Erk1/2 MAPK and mTOR signaling sequentially regulates progression through distinct stages of oligodendrocyte differentiation. Glia 60:476-486. CrossRef Medline
18. Gundimeda U, Chen ZH, Gopalakrishna R (1996) Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 271:13504 -13514. CrossRef Medline
19. Han R, Yang YM, Dietrich J, Luebke A, Mayer-Pröschel M, Noble M. (2008) Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 7:12. CrossRef Medline
20. Holt SV, Logié A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR, Wilkinson RW, Smith PD (2012) The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer 106:858-866. CrossRef Medline
21. Iusuf D, Teunissen SF, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH (2011) P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther 337:710 -717. CrossRef Medline
22. Janelsins MC, Roscoe JA, Berg MJ, Thompson BD, Gallagher MJ, Morrow GR, Heckler CE, Jean-Pierre P, Opanashuk LA, Gross RA (2010) IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice. Cancer Invest 28:544 -553. Medline
23. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R (2012) Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 18:555-567. CrossRef Medline
24. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA (2004) Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10: 2336-2343. CrossRef Medline
25. Lien EA, Solheim E, Ueland PM (1991a) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51:4837-4844. Medline
26. Lien EA, Wester K, Lønning PE, Solheim E, Ueland PM (1991b) Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 63:641-645.CrossRef Medline
27. Meyers CA, Abbruzzese JL (1992) Cognitive functioning in cancer patients: effect of previous treatment. Neurology 42:434-436. CrossRef Medline
28. Mondie CM, Vandergrift KA, Wilson CL, Gulinello ME, Weber ET (2010) The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depressionrelated behaviors in mice. Behav Brain Res 209:66-72. CrossRef Medline
29. Monje M, Dietrich J (2012) Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behav Brain Res 227:376 -379. CrossRef Medline
30. Monje ML, Mizumatsu S, Fike JR, Palmer TD (2002) Irradiation induces neural precursor-cell dysfunction. Nat Med 8:955-962. CrossRef Medline
31. Montagut C, Settleman J (2009) Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283:125-134. CrossRef Medline
32. Palmer JL, Trotter T, Joy AA, Carlson LE (2008) Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv 2:275-282. CrossRef Medline
33. Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, Vaughn CS, LoRusso PM, Cohen RB, Davies MA, Kim KB (2013) Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer 119:799-805. CrossRef Medline
34. Reddy KB, Glaros S (2007) Inhibition of the MAP kinase activity suppresses estrogen-induced breast tumor growth both in vitro and in vivo. Int J Oncol 30:971-975. Medline
35. Roberts PJ, Der CJ. (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310. CrossRef Medline
36. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640-650. CrossRef Medline
37. Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB (2010) Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 28:1294-1300. CrossRef Medline
38. Silbert LC, Nelson C, Howieson DB, Moore MM, Kaye JA (2008) Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology 71:108-113. CrossRef Medline
39. Stemmer SM, Stears JC, Burton BS, Jones RB, Simon JH (1994) White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. Am J Neuroradiol 15: 1267-1273. Medline
40. Thorburne SK, Juurlink BH (1996) Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. J Neurochem 67:1014 -1022. Medline
41. van Dam FS, Schagen SB, Muller MJ, Boogerd W, Vd Wall E, Droogleever Fortuyn ME, Rodenhuis S (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: highdose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210 -218. CrossRef Medline
42. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13:1576 -1583.CrossRef Medline